Cargando…
Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients
Intensive care unit (ICU) admissions and mortality in severe COVID-19 patients are driven by “cytokine storms” and acute respiratory distress syndrome (ARDS). Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requ...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958587/ https://www.ncbi.nlm.nih.gov/pubmed/33723251 http://dx.doi.org/10.1038/s41420-021-00429-9 |
_version_ | 1783664848331079680 |
---|---|
author | Awasthi, Samir Wagner, Tyler Venkatakrishnan, A. J. Puranik, Arjun Hurchik, Matthew Agarwal, Vineet Conrad, Ian Kirkup, Christian Arunachalam, Raman O’Horo, John Kremers, Walter Kashyap, Rahul Morice, William Halamka, John Williams, Amy W. Faubion, William A. Badley, Andrew D. Gores, Gregory J. Soundararajan, Venky |
author_facet | Awasthi, Samir Wagner, Tyler Venkatakrishnan, A. J. Puranik, Arjun Hurchik, Matthew Agarwal, Vineet Conrad, Ian Kirkup, Christian Arunachalam, Raman O’Horo, John Kremers, Walter Kashyap, Rahul Morice, William Halamka, John Williams, Amy W. Faubion, William A. Badley, Andrew D. Gores, Gregory J. Soundararajan, Venky |
author_sort | Awasthi, Samir |
collection | PubMed |
description | Intensive care unit (ICU) admissions and mortality in severe COVID-19 patients are driven by “cytokine storms” and acute respiratory distress syndrome (ARDS). Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen. In this study, 10 out of 16 patients (62.5%) that had an average plasma IL-6 value over 10 pg/mL post administration of corticosteroids also had worse outcomes (i.e., ICU stay >15 days or death), compared to 8 out of 41 patients (19.5%) who did not receive corticosteroids (p-value = 0.0024). Given this potential association between post-corticosteroid IL-6 levels and COVID-19 severity, we hypothesized that the glucocorticoid receptor (GR or NR3C1) may be coupled to IL-6 expression in specific cell types that govern cytokine release syndrome (CRS). Examining single-cell RNA-seq data from BALF of severe COVID-19 patients and nearly 2 million cells from a pan-tissue scan shows that alveolar macrophages, smooth muscle cells, and endothelial cells co-express NR3C1 and IL-6, motivating future studies on the links between the regulation of NR3C1 function and IL-6 levels. |
format | Online Article Text |
id | pubmed-7958587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-79585872021-03-15 Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients Awasthi, Samir Wagner, Tyler Venkatakrishnan, A. J. Puranik, Arjun Hurchik, Matthew Agarwal, Vineet Conrad, Ian Kirkup, Christian Arunachalam, Raman O’Horo, John Kremers, Walter Kashyap, Rahul Morice, William Halamka, John Williams, Amy W. Faubion, William A. Badley, Andrew D. Gores, Gregory J. Soundararajan, Venky Cell Death Discov Article Intensive care unit (ICU) admissions and mortality in severe COVID-19 patients are driven by “cytokine storms” and acute respiratory distress syndrome (ARDS). Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen. In this study, 10 out of 16 patients (62.5%) that had an average plasma IL-6 value over 10 pg/mL post administration of corticosteroids also had worse outcomes (i.e., ICU stay >15 days or death), compared to 8 out of 41 patients (19.5%) who did not receive corticosteroids (p-value = 0.0024). Given this potential association between post-corticosteroid IL-6 levels and COVID-19 severity, we hypothesized that the glucocorticoid receptor (GR or NR3C1) may be coupled to IL-6 expression in specific cell types that govern cytokine release syndrome (CRS). Examining single-cell RNA-seq data from BALF of severe COVID-19 patients and nearly 2 million cells from a pan-tissue scan shows that alveolar macrophages, smooth muscle cells, and endothelial cells co-express NR3C1 and IL-6, motivating future studies on the links between the regulation of NR3C1 function and IL-6 levels. Nature Publishing Group UK 2021-03-15 /pmc/articles/PMC7958587/ /pubmed/33723251 http://dx.doi.org/10.1038/s41420-021-00429-9 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Awasthi, Samir Wagner, Tyler Venkatakrishnan, A. J. Puranik, Arjun Hurchik, Matthew Agarwal, Vineet Conrad, Ian Kirkup, Christian Arunachalam, Raman O’Horo, John Kremers, Walter Kashyap, Rahul Morice, William Halamka, John Williams, Amy W. Faubion, William A. Badley, Andrew D. Gores, Gregory J. Soundararajan, Venky Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients |
title | Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients |
title_full | Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients |
title_fullStr | Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients |
title_full_unstemmed | Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients |
title_short | Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients |
title_sort | plasma il-6 levels following corticosteroid therapy as an indicator of icu length of stay in critically ill covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958587/ https://www.ncbi.nlm.nih.gov/pubmed/33723251 http://dx.doi.org/10.1038/s41420-021-00429-9 |
work_keys_str_mv | AT awasthisamir plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT wagnertyler plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT venkatakrishnanaj plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT puranikarjun plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT hurchikmatthew plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT agarwalvineet plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT conradian plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT kirkupchristian plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT arunachalamraman plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT ohorojohn plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT kremerswalter plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT kashyaprahul plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT moricewilliam plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT halamkajohn plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT williamsamyw plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT faubionwilliama plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT badleyandrewd plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT goresgregoryj plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients AT soundararajanvenky plasmail6levelsfollowingcorticosteroidtherapyasanindicatoroficulengthofstayincriticallyillcovid19patients |